CRO Sy­neos Health did­n't hold up its end of the deal in en­roll­ment for FSD Phar­ma's tri­al, ar­bi­tra­tion pan­el finds

The con­tract re­search or­ga­ni­za­tion Sy­neos Health didn’t hold up its end of the deal and use “com­mer­cial­ly rea­son­able ef­forts” when set­ting up a tri­al for a biotech client, an ar­bi­tra­tion pan­el found. It al­so de­ter­mined that the client owes the CRO about $1.7 mil­lion in dam­ages — less than half of what Sy­neos was ask­ing for in pay­ment.

FSD Phar­ma, which con­tract­ed Sy­neos to set up a Phase II tri­al in 2021 for one of its drug can­di­dates dubbed FSD 210, claimed in a state­ment Mon­day that Sy­neos failed to en­roll the ex­pect­ed num­ber of pa­tients and hit en­roll­ment dead­lines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.